Physician profile
Justine E Bunka
NPI 1720341951
$936.25
in general payments reported to CMS, 2019-2025
11 companies · $59.97 in 2025
The $59.97 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $32.92 · 2021: $125 · 2022: $165 · 2023: $135 · 2024: $264 · 2025: $59.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $450.07 | 2019-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $137.30 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Neurelis, INC. | $110.52 | 2024 | Valtoco |
| Glaxosmithkline, LLC. | $96.60 | 2019-2024 | Bexsero |
| Ironshore Pharmaceuticals INC. | $36.96 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $22.28 | 2023 | |
| Nestle Healthcare Nutrition INC. | $18.96 | 2023 | |
| Shire North American Group INC | $18.57 | 2019 | |
| Pfizer INC. | $17.81 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2023 | Flumist Quadrivalent |
| Kaleo, INC. | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justine Bunka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.